Iparomlimab

QL1706, marketed under the international nonproprietary names iparomlimab and tuvonralimab, is Qilu Pharmaceutical's MabPair. Unlike a true bispecific antibody, a MabPair is a co-formulated mixture of two separate monoclonal antibodies delivered as one drug product at a fixed molar ratio: iparomlimab (anti-PD-1, IgG4) and tuvonralimab (anti-CTLA-4, IgG1) are co-produced from a single cell line at approximately 2:1 [9]. The compound already has one approval. China's NMPA granted conditional approval in September 2024 for patients with recurrent or metastatic cervical cancer who progressed on first-line platinum-based chemotherapy, based on the single-arm DUBHE-C-206 study (n=148, ORR 33.8%, DCR 64.9%, median PFS 5.4 months) [9]. Qilu is now running at least six additional Phase 2 trials in China across cervical cancer, head and neck squamous cell carcinoma (HNSCC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and locally advanced rectal cancer [1][2][3][4][5][6]. The commercial thesis: recreate the efficacy of ipilimumab plus nivolumab, the Bristol Myers Squibb combination approved across melanoma, MSI-high colorectal, HCC, RCC, NSCLC (CheckMate 227 and 9LA), malignant pleural mesothelioma (CheckMate 743), and esophageal squamous cell carcinoma (CheckMate 648) [7][10], in a single vial that costs less to make and less for oncologists to administer, at a CTLA-4 dose meaningfully lower than the ipilimumab standard so toxicity is reduced. This remains a China-first asset. Its most direct competitor is Akeso's cadonilimab (AK104), a true PD-1 x CTLA-4 bispecific also approved for cervical cancer in China [8].

One approval in one market: NMPA conditional approval September 2024 for second-line recurrent or metastatic cervical cancer, based on DUBHE-C-206 [9]. No approvals outside China. No FDA designations (breakthrough, fast track, orphan, RMAT). Qilu has not filed with the FDA for this asset and has not publicly announced a Western partner. The active near-term development pipeline is dominated by Chinese Phase 2 trials, most of which are investigator-initiated rather than sponsored directly by Qilu, which is unusual and matters for regulatory read-through. The tracked studies: NICE-CC in neoadjuvant locally advanced cervical cancer (protocol paper published in J Gynecol Oncol 2026, n=43, primary endpoint pathological complete response, anticipated pCR 35%, results not yet reported) [1], NCT07646301 pairing QL1706 with paclitaxel and platinum in the same indication (n=103, Sun Yat-sen) [2], NCT07090317 in HNSCC (n=30, Shanghai Ninth) [3], NCT07091305 as consolidation after chemoradiotherapy in limited-stage SCLC (n=28, Shanghai Chest) [4], QUEEN-APPLE in first-line TNBC combining QL1706 with anlotinib and nab-paclitaxel (n=34, Jiangsu Cancer Institute) [5], and IT-TNT in pMMR/MSS (mismatch repair proficient / microsatellite stable, a tumor subtype that typically does not respond to checkpoint immunotherapy) locally advanced rectal cancer (n=54, Shandong Cancer Hospital) [6]. Timeline: these Phase 2s (all recruiting, all sub-105 patients) should read out sequentially over the next 12 to 24 months. Additional NMPA label-expansion filings in cervical cancer (first-line), NSCLC, or nasopharyngeal carcinoma are the plausible next regulatory milestones. Whether Qilu has filed or intends to file with FDA has not been publicly disclosed.

PD-1 is a brake pedal on T cells. Cancer cells learn to press that pedal by displaying PD-L1, which shuts off the T cells trying to kill them. Anti-PD-1 antibodies (pembrolizumab, nivolumab) block the pedal, letting T cells attack. CTLA-4 is a second, earlier brake, active mostly in lymph nodes when T cells first get primed. Blocking CTLA-4 with ipilimumab widens the pool of T cells that get activated in the first place. Blocking both is additive in some tumors and synergistic in others. Nivolumab plus ipilimumab has positive Phase 3 data and FDA approval in melanoma (CheckMate 067) [7], MSI-high colorectal, HCC, RCC, NSCLC (CheckMate 227 and 9LA), malignant pleural mesothelioma (CheckMate 743), and esophageal squamous cell carcinoma (CheckMate 648) [10]. The clinical problem is that this combination causes severe immune-related toxicity. Grade 3+ treatment-related adverse events ran at 59% in the CheckMate 067 5-year update [7] and 32% in CheckMate 648 [10]. QL1706's MabPair format combines the two antibodies as a single drug product at a fixed 2:1 iparomlimab:tuvonralimab molar ratio (PD-1 : CTLA-4) [9]. In practical terms, at the 5 mg/kg recommended Phase 2 dose that means each infusion delivers roughly two-thirds of its antibody mass as anti-PD-1 and one-third as anti-CTLA-4, well below the 3 mg/kg ipilimumab dose used in the CheckMate 067 melanoma regimen (which contained approximately 1:1 nivolumab : ipilimumab dose by weight). The Phase 1/1b study across advanced solid tumors (n=518 safety, n=468 efficacy) reported grade 3+ treatment-related adverse event rate of 16% and grade 3+ immune-related adverse event rate of 8.1% at the 5 mg/kg dose [11]. Those are substantially lower than nivolumab plus ipilimumab in melanoma or esophageal cancer, and they are the empirical basis for the entire toxicity-reduction thesis. The biology is not the question. Ipi plus nivo works. The remaining question is whether the fixed 2:1 MabPair ratio preserves efficacy at that reduced CTLA-4 exposure in randomized head-to-head data. So far the data are single-arm.

Six investigator-initiated Phase 2 trials define the current expansion data set. NICE-CC (protocol paper in J Gynecol Oncol 2026, results pending) tests QL1706 plus de-escalated chemotherapy as neoadjuvant therapy in locally advanced cervical cancer, an investigator-initiated multicenter open-label single-arm Simon two-stage design (n=43, expanding to 94 if pCR trigger met) led by Lin, Wu, Liu and colleagues [1]. NCT07646301 is a related n=103 Phase 2 at Sun Yat-sen University pairing QL1706 with paclitaxel and platinum, primary endpoint pathological complete response [2]. NCT07090317 is a small n=30 single-center HNSCC (head and neck squamous cell carcinoma) study, endpoint ORR [3]. NCT07091305 is an n=28 consolidation study in limited-stage SCLC (small cell lung cancer) after chemoradiotherapy, endpoint PFS [4]. QUEEN-APPLE (NCT07601178) is a single-arm n=34 first-line TNBC (triple-negative breast cancer) study combining QL1706 with anlotinib and nab-paclitaxel, endpoint PFS [5]. IT-TNT (NCT07026422) tests QL1706 with total neoadjuvant therapy in pMMR/MSS locally advanced rectal cancer, n=54, endpoint overall complete response rate [6]. The design concern is uniform across the program: single-arm, small, single-country, single-center or narrow multicenter, run as investigator-initiated work at academic institutions. This is fine for signal detection, insufficient as regulatory-grade evidence outside China. Any US or EU approval will require a randomized Phase 3 versus current standard of care. Qilu has separately run larger sponsor-led studies including the key DUBHE-C-206 (n=148) that supported the NMPA cervical cancer approval [9] and DUBHE-C-204 (first-line R/M cervical cancer, chemo plus or minus bevacizumab, Annals of Oncology 2024 update), but the six trials tracked in this pipeline node are the academic expansion studies, not the sponsor-led keys.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: single-arm Phase 2 data from Chinese academic centers has a documented tendency to overestimate response rates versus randomized Western studies. If ORR or pCR benchmarks against historical controls rather than a real comparator, Qilu can hit primary endpoints and still fail a subsequent randomized Phase 3. None of the six investigator-initiated trials use a biomarker selection strategy beyond routine PD-L1 or mismatch repair status. Safety risk: CTLA-4 blockade drives severe immune-mediated colitis, hypophysitis, and hepatitis, and the entire clinical rationale for the MabPair format rests on the claim that a fixed 2:1 PD-1:CTLA-4 ratio reduces toxicity relative to standard ipilimumab dosing. Phase 1 supports that claim (grade 3+ irAE 8.1% at the 5 mg/kg RP2D) [11], but until a randomized head-to-head against nivolumab plus ipilimumab exists, the toxicity advantage is inference from cross-trial comparison. Cross-trial comparisons of irAE rates are notoriously unreliable. Execution risk: Qilu has limited experience running global registrational trials in oncology, has no announced Western partner, and the regulatory pathway to FDA is unclear. Qilu Pharmaceutical is one of the largest domestic Chinese pharmaceutical companies (annual revenue on the order of USD several billion, privately held, so figures are approximate), which supports self-funded Chinese development but does not resolve the ex-China development gap. Commercial risk: cadonilimab (AK104) from Akeso is already NMPA-approved for cervical cancer and priced aggressively for the Chinese market [8]. Ipilimumab lost composition-of-matter protection in 2025 and nivolumab is expected to lose US exclusivity around 2027 to 2028 [12], meaning biosimilar combinations of nivo plus ipi could reach markets in the second half of this decade. QL1706 has to show a real toxicity advantage over the nivo plus ipi standard to price above biosimilar combos in Western markets, and randomized data supporting that toxicity advantage does not yet exist.

Worth watching, not urgent. QL1706 sits inside well-explored biology (PD-1 plus CTLA-4) with a novel delivery format (2:1 fixed-ratio MabPair) that has already cleared one regulator (NMPA, cervical cancer, September 2024) [9]. The interesting scientific question is whether the fixed-ratio format actually delivers on the toxicity-reduction claim in randomized comparison against nivolumab plus ipilimumab. Phase 1 numbers are suggestive (grade 3+ irAE 8.1% vs roughly 40-59% for the ipi+nivo standard) [11][7] but not head-to-head. The interesting commercial question is whether Qilu can convert its Chinese Phase 2 program into an NMPA label expansion (cervical first-line, NSCLC, nasopharyngeal) that scales globally through partnership, or whether a Western partner is required to run the Phase 3 that would matter to FDA and EMA. Specific data points to track: full grade 3+ irAE rates and pCR from NICE-CC when the results paper (not the protocol) publishes; any matched-cohort or head-to-head data against AK104 (cadonilimab) in cervical cancer; any partnership announcement bringing QL1706 into global development. Check back after QUEEN-APPLE (first-line TNBC, a hard indication where PD-1 monotherapy has been mixed) [5] and IT-TNT (pMMR/MSS rectal cancer is essentially checkpoint-refractory as monotherapy, so a real signal there in combination with total neoadjuvant therapy would be a big deal) [6]. Both should read out within 12 to 18 months. Sponsor to know: Qilu Pharmaceutical, one of the largest domestic Chinese pharmaceutical groups, minimal prior global oncology presence but a strong domestic pipeline.